BioLineRx (NASDAQ:BLRX) Downgraded by StockNews.com to “Sell”

BioLineRx (NASDAQ:BLRX) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Separately, HC Wainwright decreased their target price on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

BioLineRx stock traded down $0.04 during midday trading on Tuesday, reaching $3.18. 13,420 shares of the stock were exchanged, compared to its average volume of 65,048. The company’s fifty day moving average is $3.83 and its 200-day moving average is $12.15. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The firm has a market cap of $10.59 million, a PE ratio of -0.36 and a beta of 1.39. BioLineRx has a 52 week low of $2.88 and a 52 week high of $56.00.

Institutional Trading of BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.